MDS 2023 | The prognostic value of patient-reported outcomes in MDS
Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, discusses the benefits of considering patient-reported outcomes (PROs) during prognostication for myelodysplastic syndromes (MDS). Dr Efficace cites the example of patient-reported fatigue, which has been shown to provide independent prognostic information beyond the International Prognostic Scoring System (IPSS) and the revised IPSS (IPSS-R) for MDS classification. A new version of the IPSS, incorporating fatigue reports from high-risk patients with MDS (FA-IPSS[h]), has since been developed and independently validated. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy/Advisory Board: Abbvie, Syros, Incyte, Janssen
